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Colorectal cancer is closely associated with environment, diet and lifestyle. Normally it
is treated with surgery, radiotherapy or chemotherapy but increasing systemic toxicity,
resistance and recurrence is prompting scientists to devise new potent and safer
alternate prophylactic or therapeutic strategies. Among these, probiotics, prebiotics,
synbiotics, and metabiotics are being considered as the promising candidates.
Metabiotics or probiotic derived factors can optimize various physiological functions of
the host and offer an additional advantage to be utilized even in immunosuppressed
individuals. Interestingly, anti colon cancer potential of probiotic strains has been
attributable to metabiotics that have epigenetic, antimutagenic, immunomodulatory,
apoptotic, and antimetastatic effects. Thus, it’s time to move one step further to utilize
metabiotics more smartly by avoiding the risks associated with probiotics even in certain
normal/or immuno compromised host. Here, an attempt is made to provide insight into
the adverse effects associated with probiotics and beneficial aspects of metabiotics with
main emphasis on the modulatory mechanisms involved in colon cancer.
Keywords: metabiotics, metabolites, short chain fatty acids, probiotics, colorectal cancer
INTRODUCTION
Cancer refers to a heterogeneous collection of neoplastic cells evolving in microenvironments with
complex ecologies (Aktipis and Nesse, 2013). Colorectal cancer (CRC) is the third most common
cancer, affecting mainly colon and rectum in both men and women and is the second leading cause
of cancer-associated mortality (Cancer Facts and Figures, 2016). CRC affects more than 1 million
people annually, accounting for about 500,000 deaths worldwide and its incidence is increasing at
an alarming rate. Further, CRC has been predicted to affect at least half of the western population
by the age of 70 due to consumption of red or processed meat, alcoholic beverages, less fruits
and vegetables as well as lack of physical activity (Jemal et al., 2010). Recently, World Health
Organization has predicted about 27 million new cases of cancer, 17 million deaths and about 75
million people will be affected with CRC by 2030 (Kumar et al., 2015).
The etiology of CRC is complex comprising of a well-defined series of histological changes
paralleled with mutational activation of oncogenes and inactivation of tumor suppressor genes
regulated by a multifactorial interplay between diet, environment, carcinogenic chemicals, and
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mutagens (Sankpal et al., 2012; Raman et al., 2013). It has
been proposed that sporadic cancer arises due to mutant low-
penetrance genes which interact extensively with environmental
factors (Birt and Phillips, 2014). The most common driving
mutations of colon cancer affect adenomatous polyposis coli
(APC), rat sarcoma family of genes (ras), phosphatidyl inositol-
3-kinase (PI3K), and transforming growth factor (TGFβ)
(Vogelstein et al., 2013).
CRC can be treated either by surgery, radiotherapy or
chemotherapy predominantly with 5-fluorouracil and oxaliplatin
depending on the progressional stage but due to systemic
toxicity, resistance to chemotherapy and recurrence of cancer,
alternate interventions are needed. Therefore, life style and
dietary interventions such as exercise, fiber rich foods and
fermented food products have been gaining a lot of interest
by scientists round the globe for preventing colon cancer with
main focus on probiotics. Probiotics are “Live microorganisms
that, when administered in adequate amounts, confer a health
benefit on the host” as per International Scientific Association for
Probiotics and Prebiotics (Colin et al., 2014).
It is widely acknowledged that susceptibility as well as
progression of colon cancer is determined by gene-environment
interactions and microbial communities constituting micro
environment of the gut. In 400 BC Hippocrates stated ‘Death
sits in the bowel,’ implying the importance of gut microbiome
in human health and Elie Metchnikoff too linked the longevity
in Bulgarian peasants with consumption of fermented dairy
products. The gut microbiome is metabolically so active that it is
regarded as a complete organ which dynamically participates in
various physiological functions and has 10 times more cells and
100 times more genes than human body (Nicholson et al., 2012).
Colon cancer risk is influenced to a great degree by the balance
between microbial production of health-promoting metabolites
such as lactic acid, short chain fatty acids (SCFAs), linoleic
acid, some glycoproteins/peptides and potentially carcinogenic
metabolites such as amines and secondary bile acids. All these
beneficial bioactive substances associated with probiotics are
referred as either metabiotics, postbiotics, biogenics, or simply
metabolites/CFS (Cell free supernatants). The term “metabiotics”
refers to the structural components of probiotic microorganisms
and/or their metabolites and/or signaling molecules with a
determined chemical structure that can optimize host-specific
physiological functions, regulatory, metabolic and/or behavior
reactions connected with the activity of host indigenous
microbiota (Shenderov, 2013). Among these, SCFAs are the most
studied being a source of energy for colonocytes and modulator
of various metabolic activities.
No doubt probiotic bacteria with antimutagenic and/or
antigenotoxic activities, have been found to exert generalized
prophylactic effect against colon cancer but SCFAs have been
thought to be more selective in targeting cancer cells and
regulating the expression of oncogenes and tumor suppressor
genes by epigenetic mechanisms (Cousin et al., 2012; Verma
and Shukla, 2014, 2015; Papadimitriou et al., 2015). Besides
these, it has been reported that some of the gut bacteria, e.g.,
Streptococcus gallolyticus, Bacteroides fragilis, Fusobacterium have
been implicated in the genesis of CRC. More specifically, the
translocation of Streptococcus gallolyticus to blood stream has
been linked to development of inflammation and colon tumor as
well as toxin produced by Bacteroides fragilis has been shown to
cause genetic alterations due to upregulation of myc and NFκB
expression leading to CRC (Sears, 2009; Wu et al., 2009; Boleij
and Tjalsma, 2013). Furthermore, Ahn et al. (2013) and Kostic
et al. (2013) have also reported Fusobacterium to be the more
dominant bacteria in colon adenomas. Although, it is very well-
evident that probiotic microorganisms have health benefits, yet
may cause opportunistic infections, increase the incidence of
allergic sensitization and autoimmune disorders, alter the micro
ecological balance, modify gene expression, transfer antibiotic
resistance and virulence genes, lead to disorders in epigenome
and genome integrity, induce chromosomal DNA damage and
activate signaling pathways associated with cancer and other
chronic diseases in certain healthy or in immunocompromised
and high risk individuals, thereby limiting their use (Snydman,
2008; Gratz et al., 2010). To overcome such adverse effects
associated with probiotics, metabiotics are preferred due to their
known chemical structure, effective dose, safety assurance and
longer shelf-life (Shenderov, 2013).
Implications of Probiotics
Probiotics may be highly beneficial to the host as it has been
described that they can maintain epithelial integrity, compete for
adhesion and nutrition with pathogens, stimulate cell mediated
immunity, IgA production and gut associated lymphoid tissue.
Additionally, probiotics detoxify carcinogens, reduce serum
cholesterol level, alleviate lactose intolerance, produce active
metabolites including organic acids, bacteriocin, H2O2 and
enhance the production of vitamins (Kechagia et al., 2013).
Moreover, probiotics are also being used either as prophylactic or
therapeutic agent for various diseases such as antibiotic induced
or infectious diarrhea, ulcerative colitis, Crohn’s disease and
irritable bowel syndrome (Verna and Lucak, 2010). Despite
having a history of safe use, introducing live microbes in
the human body could be a potential threat especially to
immunocompromised and genetically predisposed individuals
and is a matter of concern (Pan et al., 2014). Scientists have
reported that an infant and a child without any underlying GIT
disease or immunocompromised status suffered from bacteremia
upon lactobacilli supplementation (Cabana et al., 2006). In
addition, some medical reports have also highlighted that lactic
acid bacteria and even bifidobacteria have been associated with
human opportunistic infections such as infective endocarditis,
sepsis, bacteremia, pneumonia, abdominal abscesses, peritonitis,
meningitis, urological infections, rheumatic vascular diseases in
immune compromised individuals and patients with allergic
sensitization and autoimmune disorders (Ohishi et al., 2010;
Berer et al., 2011). Though incidence of such cases may be
lower, yet depends very much on probiotic species and strain
specificity. Probiotic strains have also been found to increase
platelet aggregation and aggravate hemolytic uremic syndrome;
(Yazdankhah et al., 2009; Van Reenen and Dicks, 2011) and
are potential source of toxic metabolites like biogenic amines
in certain individuals (Bourdichon et al., 2012). It should not
be ignored that some silent genes of probiotic bacteria may be
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induced by host cell signals during passage through intestinal
tract, leading to undesirable effects (Di Caro et al., 2005).
Probiotics have also been reported to transfer genetic information
including antibiotic resistance to commensals or pathogens due
to the presence of antibiotic resistance plasmids leading to
genomic and epigenomic alterations (Shenderov, 2011).
Enterococcus faecium, having a long history of probiotic
use in preventing antibiotic-associated diarrhea, may act as
opportunistic pathogen owing to the presence of potential
reservoir of antibiotic resistance and virulence genes (Dirienzo,
2013). A recurrent septicemia and central nervous system
deterioration has also been observed in an immunocompromised
patient with spores of the probiotic strains of Bacillus subtilis
EG-RN and EG-CM (Fijan, 2014). Some studies have also
revealed increased bacterial translocation leading to mortality
upon Lactobacillus delbrueckii UFV-H2b20 and Bifidobacterium
lactis Bb12 supplementation in mice with 1,2-dimethyl hydrazine
(DMH)-induced injuries (Liboredo et al., 2010). Additionally,
some genotoxic effects have also been linked to probiotic strain
Escherichia coli Nissle 1917 possessing a set of genes (pks island)
responsible for the induction of double-strand breaks in host cell
DNA (Cuevas-Ramos et al., 2010).
It’s ironical that live microbes could potentially be risky in
immuno compromised patients where probiotic applications are
often considered, thereby emphasizing the careful examination
and application of probiotics which in turn depends upon
species and strains of probiotics and host status. Moreover,
traditional way of administering probiotics may not be able to
produce required concentration of the metabolites to produce
desired effect at the target sites in vivo. Therefore, to enhance
in situ production of beneficial metabolites, the administration
of either probiotic or specific prebiotic may be useful or
these multifunctional metabolites may be given instead of
probiotics as such but needs to be thoroughly investigated before
implementation.
Physiological Effects of Metabiotics
Probiotics colonize, multiply and produce variety of bioactive
substances “metabiotics,” accounting for their beneficial effects in
gastrointestinal tract (GIT) diseases. These metabolites produced
by probiotics help in maintaining homeostasis in the gut
and enhance the growth of friendly bacteria that inhibit the
conversion of procarcinogens into carcinogens by decreasing
harmful enzyme levels such as nitroreductase, β-glucuronidase
and β-glucosidase (Verma and Shukla, 2013; Figure 1 ‘1’). SCFAs
also induce chemopreventive enzymes glutathione S transferase
and Glutathione transferase pi (Scharlau et al., 2009; Johnson
et al., 2012) and impart genetic stability to the colon cells (Clarke
et al., 2012). Butyrate produced by fermentation of high amylose
starch was reported to reduce the overall oxidative stress in
gut and may also activate different procarcinogen metabolizing
enzymes to aid in colon cancer prevention (Treptow-van
et al., 1999). Butyrate acts as the preferred source of energy
for colonocytes and has anti inflammatory and anticancerous
properties, acetate percolates to peripheral tissues and could
be metabolized in systemic areas (muscle) and generates ATP
while propionate is transported to the liver via portal circulation
(Hijova and Chmelarova, 2007). Acetate, a multifunctional SCFA
plays significant role in regulating normal epithelial cell division,
ileal motility, and colonic blood circulation (Hong et al., 2005).
It was notable that cancer cell state was shifted from apoptosis
to necrosis in an acidic extracellular pH created by exposure
to SCFAs produced by probiotic Propionibacteria freudenreichii
(Lan et al., 2007). Liong (2008) have shown that Bifidobacterium
produced metabolites might interfere with the conversion of
azoxymethane to its active carcinogenic form and subsequently
lowered colon cancer risk. Interestingly, proteins derived from
probiotic LGG, namely p75 and p40 have been reported to
maintain gut homeostasis by regulating signaling mechanisms
(Yan et al., 2007).
Short chain fatty acids stimulate overall health of the gut
by improving mineral absorption, increasing mucosal weight,
blood circulation and gut motility, thus preventing colitis which
may gradually lead to cancer. Low pH environment created by
SCFAs inhibits 7-α-Dehydroxylase and also renders free bile acid
less soluble, hindering the generation of secondary bile acids
(Lupton, 2000). Toxic metabolites produced in the human gut
such as nitrates and oxides in response to inflammation have
also been known to influence microbial populations and hence
their metabolites formation (Bultman, 2014). Since, intestinal
tract is constantly exposed to potentially harmful substances
and toxic metabolites produced by them, it requires balancing
by protective metabolites produced by the probiotics suggesting
that an optimum balance between various metabolites ensures a
healthy gut.
Metabolites Lead to Epigenetic
Alterations
The term “epigenetics” implies modification of the expression
of certain genes induced by environmental factors without
changing their DNA sequences, such as histone modifications
(methylation, phosphorylation, deacetylation), DNA methy-
lation, chromatin remodeling as well as mechanisms mediated
by non-coding RNA molecules. Both initiation and progression
of colon cancer include breach in epigenetic regulation of cell
growth rate, differentiation and apoptosis which are influenced
to a great degree by environmental factors (Coppedè, 2014).
The epigenetic alterations paralleled with genetic mutations may
lead to transformation of normal colonic mucosa to colorectal
carcinoma. Histone deacetylases, a class of critical enzymes
cause post-translational modifications of histone proteins leading
to altered chromatin structure, influencing the binding of
transcription factors and silencing tumor suppressor genes
(Dokmanovic and Marks, 2005; Bolden et al., 2006). Further, it
has been documented that overexpression of histone deacetylase
is linked with severity of various cancers such as 62% expression
in adenomas and 82% in colorectal carcinomas compared
with 53% in normal human tissue (Ashktorab et al., 2009).
Interestingly, these epigenetic changes are potentially reversible
paving way for the discovery of a new class of drugs called
“epigenetic drugs” or histone deacetylase inhibitors (HDACi)
such as SCFAs (butyrate, acetate, propionate, and valerate)
produced by good bacteria, the Probiotics (Licciardi et al.,
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FIGURE 1 | Diagrammatic representation of colorectal cancer and various modulatory potentials of metabiotics. (A) Procarcinogens are converted to
carcinogens by enzymes leading to initiation of CRC which is accelerated by various factors such as inflammatory cytokines, genetic and epigenetic alterations
(histone hyperacetylation) resulting into hyper proliferation of colonocytes that leads to metastasis due to lack of intestinal integrity and MMP production;
(B) Metabiotics ( ) derived directly by probiotics ( ) or (C) produced as a result of prebiotic ( ) utilization by probiotic ( ) may: (1) inhibit the conversion of
procarcinogen to carcinogen by creating a low pH environment in colonic lumen and hindering the synthesis as well as activity of harmful enzymes; (2) act as HDAC
inhibitors via SMCT/MCT transporters leading to enhanced apoptosis of cancerous cells; (3) modulate inflammation by augmenting the level of anti-inflammatory
cytokines (IL-10); (4) maintain intestinal integrity by ameliorating the expression of tight junction proteins (occludins, cingulins) and inhibit MMP to impede metastasis
of cancer cells; (5) enhance the expression of GPRs, the cell surface receptors.
2010; Kim et al., 2014; Figure 1 ‘2’). These HDACi relax the
chromatin giving access to transcription factors to activate the
key target genes involved in anti cancerous effect as well as
modulates the immune response by generating T regulatory
cells (Arpaia et al., 2013; Park et al., 2015). The supernatant of
human fecal slurry and pectin has been reported to have potent
HDAC in inhibitory effects on colon cancer, due to production
of butyrate (Waldecker et al., 2008) but the epigenetic effect
of butyrate varies with type of dietary lipid intake and more
pronounced effect was observed with fish oil compared with corn
oil (Crim et al., 2008). Louis and Flint (2009) have reported
Faecalibacterium prausnitzii and Eubacterium rectal to be the
major butyrate producers in the gut. Furthermore, butyrate has
been found to have potential to differentiate between cancer
cells and normal cells in order to exert epigenetic effects and
inhibits growth of colon cancer cells mainly by de-repressing
epigenetically silenced genes such as p21 and the anti-apoptotic
protein Bcl-2 but also promotes the growth of normal cells by
regulating these genes (Zhong et al., 2014). Butyrate, the most
studied SCFA, has been attributed in induction of apoptosis
in colon cancer cells due to its ability to convert procaspase 3
to active caspase 3 (Medina et al., 1997). Furthermore, it has
been found to induce both cell cycle arrest as well as terminal
differentiation in HT-29 cells owing to the down regulation of
cell cycle regulator CB1 mRNA expression and induction of cell
cycle inhibitor p21 (Archer et al., 1998; Hinnebusch et al., 2002).
To conclude, SCFAs offer a new strategy to fight colon cancer by
acting as HDACi in order to modify all major functions such as
induction of apoptosis, cell cycle arrest and differentiation. Since
aberrant gene transcription due to epigenetic alterations is often
the underlying cause of the onset of chronic inflammation and
cancer, thus the epigenetic regulation by metabolites produced
by probiotic microorganisms (Kumar et al., 2013) emerges as
an explanation to the various anticancerous effects and suggests
metabiotics as an alternative strategy for both cancer prevention
and therapy or butyrate producers in the gut could be the target
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for enhancing in situ production of butyrate and its epigenetic
benefits.
Antimutagenic Properties Associated
with Metabiotics
Antimutagenic potential of probiotics has primarily been
attributed to binding of live bacteria with mutagens but now
there is increasing evidence that even cell free supernatants
might either scavenge the reactive carcinogen intermediates
or influence the ability of carcinogen activating/deactivating
enzymes (Treptow-van et al., 1999; Wollowski et al., 2001).
Supernatants of probiotic cultures supplemented with prebiotics
were reported to substantially reduce the genotoxicity of
human fecal slurry (Burns and Rowland, 2004). Similarly,
metabolites produced in soymilk fermented by mixed culture
of Streptococcus thermophilus, Lactobacillus acidophilus,
Bifidobacterium infantis, Bifidobacterium longum have
also been found to exhibit high antimutagenicity against
mutagen 3, 2-dimethyl-4-amino-biphenyl (Hsieh and Chou,
2006). Further, it was observed that colon cells treated
with supernatant of inulin fermentation by lactic acid
bacteria elevated Glutathione S-transferase-pi [(GST)- pi]
activity, a chemopreventive enzyme against mutagens (Scharlau
et al., 2009). The enhanced antimutagenic activity of cell
free supernatant of Lactobacillus plantarum KLAB21 was
attributed to three secretory glycoproteins 16, 11, and 14 kD
(Rhee and Park, 2001). In addition, exopolysaccharides (EPSs)
produced by Lactobacillus plantarum 301102 have also been
shown to inactivate tryptophan pyrolysate-1, another known
mutagen (Tsuda et al., 2008). Nadathur et al. (1995) prepared
acetone extracts of yogurt and showed that active metabolites
responsible for antigenotoxic activity in the extract vary
with type of carcinogen as were found to be different for
methylnitronitrosoguanidine (MNNG) and 3,2-dimethyl-4
aminobiphenyl (DMAB). In another interesting study, acetone
extracts prepared from either non-fermented milk/fermented
milk or L. acidophilus grown in MRS broth have been found
to exhibit variable antigenotoxic activity as these metabolites
prevented DNA damage in colonocytes to different degrees after
MNNG treatment. These metabolites have been found to exert
more profound antigenotoxic effect compared with cellular
components of LAB like peptidoglycan or cytoplasmic fractions
(Wollowski, 1998). However, mutagen binding potential of
probiotics (lactobacilli and bifidobacteria) has been found to
be associated with cellular components such as peptidoglycans
and polysaccharides but the antimutagenic activity very much
depends upon the growth phase, cell number of bacterial
strain and mutagen type (Raman et al., 2013). Butyrate binds
irreversibly to mutagen and is responsible for the antimutagenic
potentials exhibited by probiotic microorganisms, lactobacilli
and bifidobacteria (Stein et al., 1996; Lankaputhra and Shah,
1998). Further, butyrate enhances the production of (GST) – pi
in colon cancer cells and has also been found to inhibit the
genotoxic activity of nitrosamides and hydrogen peroxide
production in human colon cells as well as in experimental
model (Wollowski et al., 2001; Clarke et al., 2012). In addition
to butyrate; acetate, another SCFA has also been documented
to have antimutagenic properties (Christophersen et al., 2013).
Taken together, antimutagenic potential of metabiotics has been
linked with butyrate, acetate, some glycoproteins, peptidoglycans,
and polysaccharides. It can be suggested that the metabiotics
may exhibit antimutagenicity by various mechanisms such as
irreversible binding to mutagens, inhibiting carcinogen activating
enzymes, inducing chemopreventive enzymes, preventing DNA
damage and offers them unique opportunity to be nominated as
effective prophylactic agents against colorectal cancer.
Immunomodulatory Potential
Inflammation and cancer are complementary to each other and
the correlation between these was first observed by Virchow
more than a century ago by observing the presence of leukocytes
in neoplastic tissues (Francescone et al., 2014). About 20–25%
of all cancers occur as a result of chronic inflammation due
to its involvement both in tumor initiation and progression,
e.g., inflammatory bowel disease leads to colon cancer, hepatitis
to hepatocellular carcinoma and H. pylori-induced gastritis
to gastric cancer (Grivennikov et al., 2010). Chronic and
uncontrolled inflammation facilitates cancer development either
due to epigenetic alterations, genomic instability, enhanced
proliferation, invasiveness or resistance to apoptosis (Kundu
and Surh, 2012). In fact, tumor itself can recruit pro-
inflammatory cytokines, immune cells and growth factors in its
microenvironment to enhance cancer development and create
metastatic niche for secondary growth resulting into “Tumor
elicited inflammation” (Coussens et al., 2013). Interestingly,
tumor expression of oncogene k-ras upregulates the pro-
inflammatory cytokine IL-8, resulting in immune cell infiltration,
enlarged tumor and enhanced angiogenesis in colon cancer
(Sparmann and Bar-Sagi, 2004). Moreover, damaged or leaky
epithelial junctions in colon cancer too encourage vigorous
inflammatory response that in turn accelerates tumor initiation
and progression (Grivennikov et al., 2012).
Notably, degree of mucosal inflammation has been correlated
with levels, type and proportion of various SCFAs. These
metabiotics play important role in optimizing immune response
generated by intestinal epithelial cells in order to prevent
chronic inflammation. SCFAs maintain a balance by inhibiting
inflammatory cytokines such as IL-2, IL-6, and TNF-α as well
as stimulating the anti inflammatory cytokine IL-10 (Zhong
et al., 2014; Figure 1 ‘3’). SCFAs are known to regulate immune
function possibly by monitoring neutrophils, antigen presenting
cells, T-cell differentiation and histone deacetylase inhibition.
In addition, SCFAs may also interact with G-protein-coupled
receptors in the gut and affect inflammatory signaling by
regulating chemotaxis of neutrophils and other immune cells
such as dendritic cells and macrophages (Kimura et al., 2011;
Vinolo et al., 2011).
In addition to SCFAs, various bio active factors derived
from probiotics are EPSs, peptidoglycan, single layer proteins,
lipoteichoic acids, conjugated linoleic acids and peptides that
have also been found to regulate immune system (Matsuguchi
et al., 2003; Lahtinen, 2012). Zakostelska et al. (2011) emphasized
that even heat killed probiotics have equally effective anti
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inflammatory properties as live probiotics and suggested to adopt
former as the safer option for treating chronic gastrointestinal
inflammation. In nutshell, it can be stated that the efficacy
of various metabiotics in modulating inflammation has been
established using cell lines, murine models and even human
trials mainly by upregulating the synthesis of antiinflammatory
cytokines and down regulating the inflammatory mediators
(Table 1).
Antiproliferative and Apoptotic effects
Both in vitro and in vivo studies have demonstrated the significant
role of bioactive components in cell free supernatants of probiotic
strains, e.g., SCFAs (mainly butyrate) in direct inhibition of
colon cancer cell growth by various mechanisms (Table 2).
The most striking feature of butyrate is that it can differentiate
phenotypically between normal and cancer cells as it induces
differentiation, apoptosis and inhibits angiogenesis in cancerous
cells but regulates the proliferation of normal cells (Davis and
Milner, 2009).
In addition to butyrate other SCFAs, propionate and acetate
have also been reported to enhance apoptosis by affecting
the mitochondrial trans-membrane potential, generating ROS,
caspase-3-processing and causing condensation of nuclear
chromatin in colon cancer cells (Jan et al., 2002; Lan et al.,
2007; Hosseini et al., 2011). These SCFAs (propionate and
acetate) are however required in higher concentrations to induce
apoptosis and show different metabolic effects compared with
butyrate (Topping and Clifton, 2001). It has been suggested
that propionate also inhibits cancer other than in the gut as its
being easily transported to liver via portal circulation (Bindels
et al., 2012). Surprisingly, butyrate and propionate have also been
found to induce autophagy rather than apoptosis in colon cancer
cells due to some mitochondrial defects, revealing the reason
behind mixed results observed with SCFA treatment. Further, this
could result into the development of resistance in colon cancer
cells suggesting the use of autophagic inhibitors to enhance the
apoptotic effect of SCFAs (Tang et al., 2011a; Adom and Nie,
2013).
Apart from SCFAs, medium chain fatty acids such as capric,
caprylic, and caproic acids have also been reported to be
cytotoxic against colon cancer cell lines (Narayanan et al., 2015).
Additionaly; long chain fatty acids (CLA) have been found to
possess potent anticancerous effects. A commercially available
probiotic mixture VSL#3 and few strains of Bifidobacterium have
been shown to produce CLA, a potent inducer of apoptosis, COX-
2 inhibitor and activator of peroxisome proliferator-activated
receptor gamma (PPAR γ) in colon cancer and have also been
able to mitigate intestinal tumorigenesis in Apc−/+ mice (Davis
and Milner, 2009; Urbanska et al., 2009; Uccello et al., 2012).
Kim et al. (2008) reported that CFS of Bifidobacterium
adolescentis SPM0212 was more potent in inhibiting growth
of colon cancer cells than whole cells or heat killed cells.
CFS of Enterococcus lactis IW5 was also found to induce
apoptosis in various cancer cell lines including Caco-2 and HT-
29 (Nami et al., 2015). Similarly, CFS of probiotics (Lactobacillus
plantarum A7 and LGG) were more effective in inhibiting
cancer cell growth mainly due to organic acids produced by
them compared with E. coli supernatant (Sadeghi-Aliabadi et al.,
2014). In addition to organic acids, EPS (released EPSs, cell
bound EPSs) of Lactobacillus rhamnosus ATCC 9595 also showed
antiproliferative effect against HT-29 cells (Kim et al., 2006).
Recently, it was highlighted that the upregulation of early
apoptosis gene markers cfos and cjun constitutes the major
mechanism involved in cytotoxicity of cell free supernatants
of probiotic cultures toward colon cancer HT-29 and HCT116
cells (Shyu et al., 2014). Further, it has been documented that
supernatants of Lactobacillus delbrueckii were able to induce
apoptosis through intrinsic pathway and downregulation of Bcl-
2 along with arrest of colon cancer cells in G1 phase (Wan et al.,
2014). Conditioned medium of Bacillus polyfermenticus (BPCM)
effectively suppressed the growth of colon cancer cells (HT-29,
DLD-1, and Caco-2) and reduced their colony formation on soft
agar due to decreased cyclin D1, ErbB2, and ErbB3 [epidermal
growth factor receptors (EGFRs)] expression and inhibited tumor
growth in mice because of heat stable bacterial proteins (Ma
et al., 2010). LGG homogenate and cytoplasm extracts have been
found to reduce the percentage of colon cancer cell viability
to almost 55% in DLD-1 colon cancer cell lines; while heat
killed LGG reduced the viability of HT-29 and Caco-2 to 62.7
and 73% respectively (Choi et al., 2006; Orlando et al., 2009).
Very recently, it was reported that metabolites produced by new
potential probiotic strains (Pediococcus pentosaceus and Weissella
confusa) were cytotoxic against Caco-2 cell lines (Sevda et al.,
2015). Based on these inferences, it is reasonable to postulate
that metabolites produced by probiotics possess antiproliferative
activity due to their ability to induce differentiation, arrest cell
cycle and upregulate the proapoptotic mechanisms in cancer
cells which in turn depends upon the phenotypic state of cells,
probiotic strain and the active component involved.
Intestinal Integrity and Metastasis
Inhibition
Leaky gut syndrome (LGS) refers to increase in intestinal
permeability and occurs either due to irregular expression of
certain tight junction proteins or epithelial barrier dysfunction.
LGS plays important role in promoting inflammation and cancer
development by encouraging tissue invasion and metastasis. It
could be both cause and effect of gastrointestinal ailments like
inflammatory bowel disease and even colon cancer (Wang et al.,
2005). Probiotics contribute to intestinal homeostasis due to the
production of metabiotics (such as SCFAs and polyphosphates)
which exert protective gut barrier effects by regulating induction,
maintenance and assembly of tight junction proteins, production
of mucin and/or gastrointestinal peptides employed in barrier
function (Rao and Samak, 2013).
Butyrate, the major probiotic metabolite in CRC not only
acts as HDAC inhibitor and regulator of apoptosis but also
promotes intestinal epithelial barrier integrity by regulating the
expression of various tight junction proteins such as occludins
and cingulin (Bordin et al., 2004; Peng et al., 2009; Figure 1
‘4’). Caco-2 cells when treated with cell-free supernatant of
B. lactis-420 showed improved integrity of tight junctions
(Ewaschuk et al., 2008; Putaala et al., 2008). A decrease in
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TABLE 1 | Immunomodulatory potential of metabiotics in different clinical and experimental studies.
Study Reference
Intra-rectal infusion of SCFAs (80 mM sodium acetate, 30 mM sodium propionate, 40 mM sodium butyrate) twice a day
up to 6 weeks in 12 patients suffering from ulcerative colitis led to notable amelioration of inflammatory responses.
Breuer et al., 1991
Treatment of patients suffering from ulcerative colitis with twice daily SCFA enemas (sodium acetate 80 mM, sodium
propionate 30 mM, and sodium butyrate 40 mM) were helpful against colitis.
Vernia et al., 1995
Caco-2 cells treated with butyrate inhibited IL-1β-induced IL-8 mRNA expression and suppressed NFκB by inhibiting
both its nuclear translocation as well as DNA binding and induction of IκB-β.
Wu et al., 1999
Metabolites produced by Streptococcus thermophilus and Bifidobacterium breve inhibited TNF-α secretion from
lipopolysaccharide treated peripheral blood mononuclear cells or the THP-1 cell line.
Menard et al., 2004
Intestinal epithelial cells grown with conditioned media containing VSL#3-produced conjugated linoleic acids (CLA)
enhanced PPARγ and CD36 expression by suppressing TNF-α and MCP-1 colonic expression in comparison to VSL#3
or linoleic acids alone.
Ewaschuk et al., 2006
The proteins p40 and p75 obtained from LGG activated protein kinase B and inhibited TNF-α. Yan et al., 2007
The supernatant of Faecalibacterium prausnitzii DSM 17677 suppressed IL-1β-induced NFκB activation. Sokol et al., 2008
Immunomodulation and anti colon cancer effect exhibited by Lactobacillus casei Shirota was attributed to a
polysaccharide–peptidoglycan complex.
Matsumoto et al., 2008
A QS system related peptide produced by B. animalis lactis BB-12 enhanced the expression of c-myc and IL-6. Mitsuma et al., 2008
L. reuteri secreted factors decreased NFκB p65 nuclear translocation by suppressing IκBα ubiquitination and
modulated MAPK signaling.
Iyer et al., 2008
A small, heat stable and water-soluble anti inflammatory factor produced by Saccharomyces boulardii prevented the
activation of NFκB reporter gene and IκBα degradation in THP-1 cells, leading to inhibition of p65 nuclear translocation
and NFκB DNA binding.
Sougioultzis et al., 2006
An exopolysaccharide PSA, a cell wall component of Bacteroides fragilis reproduced the potent anti inflammatory
effects as that of parent bacteria both in vitro and in vivo.
Round and Mazmanian, 2010
Bacterial extracts of LGG and B. adolescentis given to rats significantly activated macrophages to enhance the
production of TNF-α and nitric oxide.
Lee et al., 2008; Bertkova et al., 2010;
Switzer et al., 2011
Short chain fatty acids regulated chemotaxis of neutrophils dependent on GPR43 activation and other immune cells
such as dendritic cells and macrophages.
Vinolo et al., 2011
The purified soluble protein p40 from Lactobacillus rhamnosus GG exerts anti-inflammatory effects in murine colitis
model.
Yan et al., 2011
Furanosyl borate diester produced by Escherichia coli Nissle1917 induced the production of anti inflammatory cytokines
by influencing the gene expression of luxS.
Jacobi et al., 2012
Conjugated leinoleic acids suppress TNF-α and MCP-1 colonic expression and reproduce the effects of VSL#3
administration in mice with Disodium sulfate colitis.
Bassaganya-Riera et al., 2012a,b
Butyrate treatment improved mucosal health of colitis murine model by restoring cytokine balance, normal crypt length
and reducing the severity of inflammation.
Vieira et al., 2012
Oral administration of butyrate controlled T cell-induced colitis in lymphocyte deficient mice and ameliorated
inflammation in mice models for ulcerative colitis.
Vieira et al., 2012; Furusawa et al.,
2013
Various SLPs on the surface of Propionibacterium freudenreichii ITGP20 contribute to the induction of IL-10 and IL-6. Le Marechal et al., 2014
colonic permeability was also recorded by oral administration
of bioactive factors from B. infantis in murine colitis model
(Segawa et al., 2011). Metabolites produced by B. infantis Y1
increased ZO-1 and occludin expression in T cells (Rao and
Samak, 2013). It has been observed that surface components of
probiotic microorganisms such as pilus, lipoteichoic acids, and
mucus binding proteins interact directly with both epithelial and
immune cells of the host to maintain gut barrier homeostasis. In
addition, Patel et al. (2012) reported an interesting observation
that even heat-killed LGG regulated intestinal barrier in mice
with abnormal gut. Recently p40, a soluble protein produced
by LGG has been found to enhance the chemical barrier by
activating EGFR which in turn stimulates goblet cells to produce
mucin (Wang et al., 2014). Both p40 and p75 protect not only the
epithelial tight junctions against oxidative stress through MAP
kinase signaling pathways but also inhibit the redistribution
of tight junction proteins induced by hydrogen peroxide (Seth
et al., 2008). Cell-free conditioned media of LGG has also
been observed to induce the production of cytoprotective
heat shock proteins (hsp25, hsp72) by intestinal epithelial
cells which promote tight junctions (Thomas and Versalovic,
2010). LGG supernatant is capable of reversing the epithelial
barrier dysfunction induced by alcohol, both in vitro as well as
in vivo and have been found to regulate levels of claudin-1,
ITF, P-gp and cathelin-related antimicrobial peptide to
re- establish intestinal barrier functions (Wang et al., 2011,
2012). Competence and sporulation factor (CSF), a quorum-
sensing peptide produced by Bacillus subtilis JH642 has the
potential to induce hsp25, hsp27, and hsp72 in intestinal
epithelial cells (Fujiya et al., 2007). It has also been observed
that proteins derived from Clostridium butyricum CGMCC0313-
1 regulate the intestinal barrier function by enhancing
the expression of protein A20 in HT-29 cells (Song et al.,
2012).
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TABLE 2 | Anti proliferative and apoptotic effect of butyrate in colon cancer.
Study Reference
Butyrate treatment reduces the colony forming ability of cancer cells as observed on soft agar along with induction of
alkaline phosphatase in colon cancer cell lines.
Topping and Clifton, 2001
Butyrate modulates apoptosis even in genetically damaged cells both via extrinsic as well as intrinsic pathways mainly
by upregulation of the proapoptotic protein BAK, caspase-3-mediated cleavage of poly-(ADP-ribose) polymerase
(PARP) and downregulation of neuropilin-1, the key apoptotic and angiogenesis regulator of tumor cells.
Ruemmele et al., 2003; Yu et al., 2010
The administration of butyrate producing bacteria, Butyrivibrio fibrisolvens MDT-1 to experimental model of CRC
resulted in a significant decline in ACF and β glucuronidase levels.
Fotiadis et al., 2008
Butyrate reduces the development of colon cancer by reducing the expression of vital genes, cyclin D1 and c-myc. Maier et al., 2009
Anti cancerous potential of butyrate has been due to its ability to suppress miRNAs which are overexpressed in colon
cancer. Altered expression of at least 44 miRNAs in HCT-116 cells as well as increased expression of p21 has been
assessed due to the suppression of miR-106b on treatment with butyrate.
Hu et al., 2011
Hyperactivation of WNT/beta-catenin signaling pathway constitutes the major mechanism of butyrate to induce
apoptosis in colon cancer cells.
Zeng et al., 2014
Combination of sodium butyrate together with a polyphenol, epigallocatechingallate (EGCG) proved to have synergistic
effect against colon cancer as it induced significant degree of apoptosis, decreased colony forming capability of cancer
cells by 80% and cell cycle arrest in different colon cancer cell lines (RKO, HCT-116 and HT-29). In addition to these, the
expression of p21 and p53 were upregulated while HDAC and the caspase inhibitory protein, survivin were
downregulated.
Saldanha et al., 2014
Butyrate treatment led to cell injury due to decreased adhesion and increased granulation of HCT-116 colon cancer cell
lines.
Kazemi sefat et al., 2015
Metastasis is the major cause of mortality in cancer patients.
Metastasis or excessive proliferation and invasion of cancerous
cells occurs due to degradation of extracellular matrix by enzyme
matrix metalloproteinases (MMPs) and MMP-9 levels have been
significantly correlated with the stage of colon cancer (Baker and
Leaper, 2002; Leeman et al., 2003; Mook et al., 2004). Colorectal
cancer metastasis occurs due to loss of tight junction proteins
such as occludin, ZO-1 and clodulin-4 (Kaihara et al., 2003;
Tobioka et al., 2004; Ohtani et al., 2009). Escamilla et al. (2012)
have demonstrated that metabolites produced by L. casei and
LGG potentially interfere with metastatic process in colorectal
cancer by decreasing MMP-9 activity and increasing the levels of
ZO-1 in HCT-116 cells. Butyrate hindered the activity of MMPs
due to activation of tissue inhibitor matrix metalloproteinase
(TIM) 1- and 2 (Adom and Nie, 2013). Another study observed
that supernatants of Lactobacillus delbrueckii ameliorated cell
invasion in colon cancer cells by decreasing MMP-9 activity
(Wan et al., 2014). Further, it was revealed that fermented
products of synbiotic (inulin and oligofructose with LGG and/or
Bifidobacterium lactis BB12) inhibited cell invasion both in vitro
and in experimentally induced colon carcinogenesis in rats (Pool-
Zobel, 2005; Pool-Zobel and Sauer, 2007). In nutshell, it can
be stated that metabolites produced by probiotics offer a safe
and effective tool for combating colon cancer by their ability to
maintain the intestinal integrity; regulating tight junctions and to
inhibit metastasis by decreasing MMP activity.
Receptors and Transporters Associated
with Biological Actions of Metabiotics
Continuous extensive research on the interaction of bacterial
metabolites especially SCFAs with host has advanced toward
the molecular approach of butyrate and other SCFAs toward
their modulatory mechanisms in colon, both extracellularly
(via activating specific receptors) and intracellularly (via
transportation mediated by specialized transporters) (Ganapathy
et al., 2013). SCFAs synthesized by friendly bacteria in the lumen
of colon could be absorbed passively or carried via transporters
like SMCT1/SLC5a8 and MCT1/SLC16a1 into colonocytes.
SMCT1 and MCT1 are sodium-coupled monocarboxylate
transporter and H+-coupled transporter respectively. Despite the
presence of SMCT1 along entire length of the large intestine,
MCT1 found in apical membrane of colonocytes accounts for
the major transport of SCFAs and could be transported either
by apical or basolateral membrane of colonocytes. MCT1 is also
expressed on the apical membrane of dendritic cells, kidney cells,
and even brain cells and is downregulated during early adenoma
formation accompanied with enhanced expression of the high
affinity glucose transporter, GLUT1 and reduced expression of
the low affinity glucose transporter GLUT2 (Lambert et al., 2002).
Undissociated SCFAs can passively diffuse across the apical
membrane of epithelial cells lining but due to acidic intestinal
pH; most of the SCFAs are dissociated and have to be transported
actively via transporters (Sellin, 1999). Scientists have proposed
three fundamental mechanisms for the active transport of SCFAs
including SCFA-HCO3− exchange, electroneutral SCFA anion
cotransport with cations mediated by MCT1 and electrogenic
sodium-dependent transport carried out by SMCT1 (Besten et al.,
2013). Gonçalves et al. (2011) have reported that butyrate is
transported faster from apical membrane of colonocytes via
SMCT-1 compared with acetate and propionate and essential for
histone deacetylase inhibition (Li et al., 2003; Gopal et al., 2004;
Miyauchi et al., 2004). SCFAs not only enter colonocytes but also
the immune cells via SMCT1 thereby hindering the inflammatory
signal by blocking the generation of dendritic cells from bone
marrow stem cells (Singh et al., 2010).
Short chain fatty acids are not fully consumed by colonocytes
but have to be transported actively across their basolateral
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membrane via cation-SCFA anion symport or SCFA -HCO3−
antiport and is proposed to be mediated by MCT4 (SLC16A3)
and MCT5 ( SLC16A4) (Gill et al., 2005). SCFAs can also enter
other organs such as liver and muscle via portal circulation.
The transporters for butyrate and propionate across sinusoidal
membrane of liver cells have been identified as the organic anion
transporters OAT7 and OAT2 respectively (Shin et al., 2007;
Islam et al., 2008).
Receptors present on different cells play important role in
pathophysiology of various diseases. GPR 109A and GPR43/free
fatty acid receptor (FFA2) are cell- surface G-protein-coupled
receptors expressed on the colonic epithelium, adipose tissue, and
immune cells which are activated by SCFAs (Blad et al., 2012;
Figure 1 ‘5’). GPR41/free fatty acid receptor 3 (FFA3) is another
receptor found on colonocytes, adipocytes, spleen, lymph nodes,
bone marrow, renal smooth muscle cells, enteric neuronal cells,
and pancreatic cells (Xiong et al., 2004; Kim et al., 2014). Butyrate
and niacin (Vitamin B3) are the known potential agonists for
GPR109A while acetate and propionate are for GPR 43 receptors
(Bindels et al., 2013). FFA2 has higher affinity for both acetate
and propionate and is present primarily in immune cells whereas
FFA3 has greater affinity for butyrate and propionate but has
highest expression in adipose tissue (Brown et al., 2003; Le Poul
et al., 2003; Nilsson et al., 2003). However, FFA2 suppresses
inflammation in healthy colon as reduced expression of GPR43
has been found both at the primary site of tumor as well as
the metastatic sites in CRC. Further, cancer cells with increased
expression of GPR43 were found to be more susceptible for
apoptosis and cell cycle arrest caused by SCFAs (Tang et al.,
2011b). Acetate, has been able to impart protection to germ-free
mice from dextran sulfate sodium (DSS) induced colitis by acting
as a GPR43 Singh et al. (2014). The expression of neuropilin-1
(receptor for VEGF) has been inversely correlated with levels of
SCFAs in colon and has been shown to be reduced by butyrate in
colon cancer cell lines (Yu Danny et al., 2011).
GPR109A and SLC5A8 (SMCT1) both aid significantly in
enhancing apoptosis induction potential of butyrate which
implies both extracellular as well as intracellular regulation
(Andoh et al., 2003; Thangaraju et al., 2008). GPR109A is
responsible for enabling macrophages and dendritic cells to
differentiate T regulatory cells and induce production of anti-
inflammatory cytokines as evident by the ability of induction
of expression of IL-18 in colonic epithelium by butyrate and
niacin in WT mice (possessing GPR109A) but inability to
do so in case of Niacr1-/- mice (lacking GPR109A) (Singh
et al., 2014). This study has shown that animals deficient in
GPR109A are more susceptible to both inflammation-induced
and mutated Apc driven colon carcinogenesis. Cresci et al.
(2010) reported that the levels of SLC5A8 mRNA and GPR109A
mRNA in colon were markedly reduced in germ-free mice
but restored with recolonization of the gut microflora by
maintaining conventional conditions for 3–4 weeks as gut
bacteria play important role in the expression of both receptors
and transporters of SCFAs. Moreover, optimal dietary fiber intake
increases the concentration of SCFAs in the gut lumen leading
to entry of butyrate and other HDAC inhibitors into the cell
even without SLC5A8 via direct diffusion or by other low affinity
monocarboxylate transporters such as SLC16A1. But SLC5A8
becomes indispensable in case of low dietary fiber intake, as
SCFAs in low concentrations will not be able to diffuse or enter
the cell via low affinity transporters. However, GPR109A and
GPR43 are essential for extracellular functions of SCFAs in the
presence of both, optimal as well as low dietary fiber intake.
The immune modulating activity of either probiotic or
metabiotic is thought to be due to binding of SCFAs to GPRs,
that helps in recruitment of immune cells, activation of effector
T cells and production of cytokines and chemokines (Sina et al.,
2009; Smith et al., 2013). SCFAs have been extensively involved
in the modulation of the expression of both receptors and
transporters associated with various cells which hold paramount
importance in pathogenesis of CRC. Thus, it can be stated that
the interactions between SCFAs and these receptors/transporters
need to be explored to reveal the molecular mechanism of action
of metabiotics.
FUTURE DIRECTIONS
Although, it may take a while to unravel and utilize the
remarkable attributes associated with metabiotics against
colon cancer but it seems quite possible due to increasingly
overwhelming studies emerging in this direction such as
commercialized metabiotics, ‘Hylak Forte’ (Lactic acid and
SCFAs) and ‘Zakofalk’ (Inulin and butyrate) derived from
multiple probiotics to promote general health and to treat
moderate inflammatory conditions respectively (Belousova
et al., 2005; Roda et al., 2007). Moreover, probiotic strains
should be screened for specific potential metabiotics in their
cell free supernatants as there is much ground to be covered
yet. However, delivery of metabiotics to the right place (i.e.,
distal colon) however remains a challenge in CRC which could
be met by devising new strategies of targeted delivery. The fact
that metabiotics affect gene expression even at translational
level by altering miRNAs has added another dimension to their
mechanistic study but warrants detailed investigation. Though
considerable amount of in vitro work regarding the undeniable
role of metabiotics in colon cancer has been accomplished but
intensive in vivo studies followed by placebo controlled, double
blind clinical trials need to be performed.
CONCLUSION
Probiotics are known to exert various health benefits such
as immunomodulation, inactivation of carcinogens and
maintenance of gut integrity but the present review argues
the notion that live probiotic strains are essential for the
beneficial effects associated with them in colon cancer. Moreover,
adverse effects associated with probiotics even in certain
normal/or immunosupressed individuals limit their use.
Thus, attempts are being made to have alternative safer and
effective biointerventions such as metabiotics and to enhance
their in situ production by selectively optimizing the growth
conditions for beneficial probiotics. Moreover, metabiotics, the
multifunctional metabolites produced by probiotics have been
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found to possess remarkable antimutagenic, antiinflammatory,
antiproliferative and even antimetastatic potentials attributed to
their epigenetic effects in one or other way, and may target
CRC at different stages. This information suggests that the
administration of metabiotics may attenuate both the adverse
effects as well as worry of maintaining the viability of probiotics.
Thus, metabiotics independently or in conjunction with other
approaches could be considered as a potent prophylactic/or
therapeutic modulator for colon cancer or other diseases in the
post-antibiotic era.
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